About US
Contact us
-
FDA yanks chloroquine's emergency OK after data show it doesn't work against COVID-19It's been more than 2 months since President Donald Trump touted malaria drugs as a possible "game-changer" for coronavirus treatment, and the FDA quickly signed off on their emergency use during the2020/6/17
-
Eli Lilly, spurred by AI analysis, starts pivotal study of arthritis med Olumiant in COVID-19As drugmakers mobilize to repurpose existing medicines for COVID-19, Eli Lilly is hoping its arthritis med Olumiant could play a part. The Indianapolis pharma haskicked offa phase 3 clinical trial te2020/6/16
-
AstraZeneca spinoff Viela Bio scored its first FDA nod. Can it face down heavyweight rivals?Two years after launching, AstraZeneca spinoffVielaBio has its first FDA approval inUplizna following Friday'snodto treat certainpatients with neuromyelitisopticaspectrum disorder. Analysts expect th2020/6/16
-
Net prices decline in the first quarter, but the political threat returnsWith the U.S. presidential race and Senate contests getting into high gear, one prominent biopharma analyst sees warning signs for the industry. Meanwhile, net prices fell in the first quarter, and t2020/6/15
-
AbbVie's Skyrizi bests Novartis' Cosentyx in head-to-head psoriasis matchWith its megamerger with Allergan closed and Humira's decline staring it in the face, AbbVie is looking for growth from its two recent launches, psoriasis med Skyrizi and rheumatoid arthritis drug Ri2020/6/15
-
AstraZeneca's Farxiga cuts risk of diabetes onset in heart failure patientsAstraZeneca diabetes drug Farxiga last month scored a first-in-class FDA nod, winning clearance to reduce cardiovascular risks for certain heart failure patients without diabetes. Now, the British dr2020/6/12
-
Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2Novo Nordisk has long been working on drugs that can help people earlier on in their diabetes and keep them from progressing to insulin treatment. But that doesn’t mean it’s not also working to impro2020/6/12
-
Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data showEli Lilly is fighting hard to protect Trulicity's share against Novo Nordisk’s newest offerings in the GLP-1 class, and it’s breaking out real-world data to support its case. A new real-world analysi2020/6/11
-
Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugarSanofi’s Soliqua combines an insulin with a GLP-1 agonist, and, according to a new real-world study, delivering those two therapies simultaneously is the way to go. Starting an insulin and a GLP-1 dr2020/6/11
-
AstraZeneca ditches plan for Gilead merger amid industry skepticism: reportThe excitement over a potential record-setting megamerger between AstraZeneca and Gilead Sciences looks short-lived. AstraZeneca has already ditched its interest in a marriage with Gilead, The Times2020/6/10